In this short report, we first aimed to characterize the expression of such immune checkpoint molecules, both on CD34+ AML cells and on CD34− bone marrow cells and on blood and bone marrow (BM) resident T cells during the treatment course. Here, CD34 is linked to acute myeloid leukemia.